Abstract
Malignant brain tumours are complex ecosystems containing neoplastic and stromal components that generate adaptive and evolutionarily driven aberrant tissues in the central nervous system. Brain cancers are cultivated by a dynamic population of stem-like cells that enforce intratumoural heterogeneity and respond to intrinsic microenvironment or therapeutically guided insults through proliferation, plasticity and restructuring of neoplastic and stromal components. Far from a rigid hierarchy, heterogeneous neoplastic populations transition between cellular states with differential self-renewal capacities, endowing them with powerful resilience. Here we review the biological machinery used by brain tumour stem cells to commandeer tissues in the intracranial space, evade immune responses and resist chemoradiotherapy. Through recent advances in single-cell sequencing, improved models to investigate the role of the tumour microenvironment and a deeper understanding of the fundamental role of the immune system in cancer biology, we are now better equipped to explore mechanisms by which these processes can be exploited for therapeutic benefit.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 22, iv1–iv96 (2020).
Ostrom, Q. T., Wright, C. H. & Barnholtz-Sloan, J. S. Brain metastases: epidemiology. Handb. Clin. Neurol. 149, 27–42 (2018).
Sacks, P. & Rahman, M. Epidemiology of brain metastases. Neurosurg. Clin. N. Am. 31, 481–488 (2020).
Desai, A., Yan, Y. & Gerson, S. L. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cell Transl. Med. 8, 75–81 (2019).
Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).
Ahn, J. H. et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature 572, 62–66 (2019).
Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326–341 (2017).
Wolf, K. J., Chen, J., Coombes, J., Aghi, M. K. & Kumar, S. Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nat. Rev. Mater. 4, 651–668 (2019).
Tykocki, T. & Eltayeb, M. Ten-year survival in glioblastoma. A systematic review. J. Clin. Neurosci. 54, 7–13 (2018).
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251 (2021). This article provides the most updated and authoritative review of the World Health Organization classification of brain tumours, including an expanded role for molecular testing in diagnosis and classification.
Wang, L. B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell https://doi.org/10.1016/j.ccell.2021.01.006 (2021).
Cabrera, M. C., Hollingsworth, R. E. & Hurt, E. M. Cancer stem cell plasticity and tumor hierarchy. World J. Stem Cell 7, 27–36 (2015).
Lauko, A., Lo, A., Ahluwalia, M. S. & Lathia, J. D. Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2021.02.014 (2021).
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C. & Kuperwasser, C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 24, 65–78 (2019).
Mitchell, K., Troike, K., Silver, D. J. & Lathia, J. D. The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions. Neuro Oncol. 23, 199–213 (2021).
Chaligne, R. et al. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states. Nat. Genet. 53, 1469–1479 (2021).
Syms, P. Evolution of cancer of the breast. J. Am. Med. Assoc. LXIX, 454–459 (1917).
Windholz, F. Problems of acquired radioresistance of cancer; adaptation of tumor cells. Radiology 48, 398–404 (1947).
Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).
Hansen-Melander, E. Accelerated evolution of cancer stemlines following environmental changes. Hereditas 44, 471–487 (1958).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012).
Liu, G. et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
Bao, S. et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843–7848 (2006).
Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139–152 (2013).
Wakimoto, H. et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472–3481 (2009).
Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829–833 (2010). Together with Ricci-Vitiani et al. (2010), this article describes a lineage plasticity phenomenon whereby GSC populations promote angiogenesis and generation of tumour vasculature through transdifferentiation into neoplastic endothelial cells, with later work by Cheng et al. (2013) identifying further transdifferentiation into pericyte lineages.
Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42–56 e46 (2017). This article describes the most widely accepted cell-intrinsic transcriptional glioblastoma classification scheme, defining proneural, mesenchymal and classical transcriptional subgroups, updating previous work by Verhaak et al. (2010), and further delineating microenvironmental impacts on these states.
Liau, B. B. et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233–246 e237 (2017).
Wang, J. et al. Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive-feedback loop. Nat. Neurosci. 22, 91–105 (2019).
Bayin, N. S. et al. Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget 8, 64932–64953 (2017).
Zhu, T. S. et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71, 6061–6072 (2011).
Rajakulendran, N. et al. Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells. Genes Dev. 33, 498–510 (2019).
Zheng, H. et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 17, 497–509 (2010).
Hu, B. et al. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell 167, 1281–1295 e1218 (2016).
Binda, E. et al. Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells. Cancer Res. 77, 996–1007 (2017).
Huang, M. et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci. Transl. Med. 12 https://doi.org/10.1126/scitranslmed.aay7522 (2020).
Rheinbay, E. et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 3, 1567–1579 (2013).
Manoranjan, B. et al. A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene 39, 1590–1599 (2020).
Guryanova, O. A. et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19, 498–511 (2011).
Hossain, A. et al. Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cell 33, 2400–2415 (2015).
Jin, X. et al. The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in glioblastoma stem cells. Cell Rep. 16, 1629–1641 (2016).
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I. & Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165–172 (2007).
Bleau, A. M. et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226–235 (2009).
Anido, J. et al. TGF-beta receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655–668 (2010).
Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839–852 (2013).
Jin, X. et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat. Med. 23, 1352–1361 (2017).
Sachamitr, P. et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat. Commun. 12, 979 (2021).
Flavahan, W. A. et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 16, 1373–1382 (2013).
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. & Rich, J. N. Cancer stem cells in glioblastoma. Genes. Dev. 29, 1203–1217 (2015).
Bahmad, H. F. & Poppiti, R. J. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. J. Clin. Pathol. 73, 243–249 (2020).
Parker, M. et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506, 451–455 (2014).
Kupp, R. et al. ZFTA translocations constitute ependymoma chromatin remodeling and transcription factors. Cancer Discov. 11, 2216–2229 (2021).
Arabzade, A. et al. ZFTA-RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma. Cancer Discov. 11, 2200–2215 (2021).
Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27, 728–743 (2015).
Mack, S. C. et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 553, 101–105 (2018).
Taylor, M. D. et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8, 323–335 (2005).
Lan, X. et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 549, 227–232 (2017).
Dirkse, A. et al. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 10, 1787 (2019).
Suva, M. L. & Tirosh, I. The glioma stem cell model in the era of single-cell genomics. Cancer Cell 37, 630–636 (2020).
Castellan, M. et al. Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma. Nat. Cancer 2, 174–188 (2021).
Lee, J. H. et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560, 243–247 (2018). Through deep sequencing of primary patient-derived tumour and matched normal tissues along with lineage tracing experiments in mice, this work provides evidence that astrocyte-like neural stem cells in the subventricular zone serve as a developmental origin for glioblastomas.
Bhaduri, A. et al. Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell 26, 48–63 e46 (2020).
Alcantara Llaguno, S. et al. Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nat. Neurosci. 22, 545–555 (2019).
Alcantara Llaguno, S. R. et al. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28, 429–440 (2015).
Wang, Z. et al. Cell lineage-based stratification for glioblastoma. Cancer Cell 38, 366–379 e368 (2020).
Bressan, R. B. et al. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants. Cell Stem Cell 28, 877–893 e879 (2021).
Haag, D. et al. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. Cancer Cell 39, 407–422 e413 (2021).
Funato, K., Smith, R. C., Saito, Y. & Tabar, V. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma. Cell Stem Cell 28, 894–905 e897 (2021).
Couturier, C. P. et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 11, 3406 (2020).
Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835–849 e821 (2019). This large-scale single-cell sequencing and lineage tracing effort defines four transcriptional states in glioblastoma with a high degree of phenotypic plasticity that is partly informed by underlying genetic factors and developmental lineages as well as microenvironmental inputs.
Wang, L. et al. The phenotypes of proliferating glioblastoma cells reside on a single axis of variation. Cancer Discov. 9, 1708–1719 (2019).
Guilhamon, P. et al. Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. eLife 10 https://doi.org/10.7554/eLife.64090 (2021).
Garofano, L. et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat. Cancer 2, 141–156 (2021).
Schmitt, M. J. et al. Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing. Cancer Discov. 11, 754–777 (2021).
Hara, T. et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39, 779–792 e711 (2021).
Cavalli, F. M. G. et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31, 737–754 e736 (2017).
Northcott, P. A. et al. The whole-genome landscape of medulloblastoma subtypes. Nature 547, 311–317 (2017).
Zhang, L. et al. Single-cell transcriptomics in medulloblastoma reveals tumor-initiating progenitors and oncogenic cascades during tumorigenesis and relapse. Cancer Cell 36, 302–318 e307 (2019). Through single-cell sequencing approaches, this work elucidates the role of OLIG2+ stem-like populations in the initiation of medulloblastomas and in tumour repopulation following therapy through activation of stem and proliferative signalling pathways.
Vladoiu, M. C. et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature 572, 67–73 (2019).
Gojo, J. et al. Single-cell RNA-Seq reveals cellular hierarchies and impaired developmental trajectories in pediatric ependymoma. Cancer Cell 38, 44–59 e49 (2020). This article describes the intratumoural heterogeneity and developmental origins of paediatric ependymomas, defining three main developmental subgroups and highlighting the importance of undifferentiated progenitor populations in the maintenance of cellular hierarchies and disease aggressiveness.
Gillen, A. E. et al. Single-cell RNA sequencing of childhood ependymoma reveals neoplastic cell subpopulations that impact molecular classification and etiology. Cell Rep. 32, 108023 (2020).
Panwalkar, P. et al. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Sci. Transl. Med. 13, eabc0497 (2021).
Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318–328 (2015). Together with Wang et al. (2016), this article interrogates the evolution of glioblastomas over time, revealing substantial divergence between primary and recurrent specimens and suggesting a branched evolution model whereby evaluation of the primary tumour biopsy sample may not be representative of later recurrences.
Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).
Lee, J. K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 49, 594–599 (2017).
Korber, V. et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 35, 692–704 e612 (2019).
Klughammer, J. et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat. Med. https://doi.org/10.1038/s41591-018-0156-x (2018).
Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019). Through analyses of molecular features, including mutations and copy number variation, this report suggests that diffuse gliomas undergo a largely neutral evolution process driven by stochastic mutations rather than clonal selection, while high-grade wild-type IDH gliomas displayed the largest proportion of clonal selection events.
Miller, A. M. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565, 654–658 (2019).
Gao, X. et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. Nat. Cell Biol. 23, 278–291 (2021).
Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76 (2014). This is among the first reports to document the presence of extrachromosomal circular DNA elements in glioblastomas and to describe the mechanisms by which dynamic control of these DNA elements drives EGFR-targeted therapeutic resistance, highlighting the importance of non-chromosomal DNA replication, segregation and regulation in cancer biology.
Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122–125 (2017).
deCarvalho, A. C. et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat. Genet. 50, 708–717 (2018).
Morton, A. R. et al. Functional enhancers shape extrachromosomal oncogene amplifications. Cell 179, 1330–1341 e1313 (2019).
Recasens, A. & Munoz, L. Targeting cancer cell dormancy. Trends Pharmacol. Sci. 40, 128–141 (2019).
Kleffel, S. & Schatton, T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv. Exp. Med. Biol. 734, 145–179 (2013).
Adamski, V. et al. Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by temozolomide and AT101 treatment. Oncotarget 8, 108064–108078 (2017).
Zhu, Z. et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 15, 185–198 (2014).
Richichi, C., Brescia, P., Alberizzi, V., Fornasari, L. & Pelicci, G. Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma. Neoplasia 15, 840–847 (2013).
Tejero, R. et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine 42, 252–269 (2019).
Atkins, R. J. et al. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Exp. Cell Res. 374, 353–364 (2019).
Eyler, C. E. et al. Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance. Genome Biol. 21, 174 (2020).
Rabe, M. et al. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis. 11, 19 (2020).
Jane, E. P. et al. Targeting NAD+ biosynthesis overcomes panobinostat and bortezomib-induced malignant glioma resistance. Mol. Cancer Res. 18, 1004–1017 (2020).
Rusu, P. et al. GPD1 specifically marks dormant glioma stem cells with a distinct metabolic profile. Cell Stem Cell 25, 241–257 e248 (2019).
Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93–98 (2015).
Wang, X. et al. Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell 22, 514–528 e515 (2018).
Kim, D. et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520, 363–367 (2015).
Man, J. et al. Hypoxic induction of vasorin regulates notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell 22, 104–118 e106 (2018).
Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17, 1556–1568 (2015).
Villa, G. R. et al. An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell 30, 683–693 (2016).
Zhang, H., Zhou, Y., Cui, B., Liu, Z. & Shen, H. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. Biomed. Pharmacother. 126, 110086 (2020).
Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824–828 (2010).
Zhou, W. et al. Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy. Cell Stem Cell 21, 591–603 e594 (2017).
Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803–816 (2015). In a series of studies using optogenetic control mechanisms, Venkatesh et al. (2015, 2017 and 2019) delineate the critical role of neuronal activity in the tumour microenvironment in supporting brain tumour growth via a neuroligin 3–PI3K–mTOR signalling axis, as well as the functional integration of gliomas into electrical circuits and synaptic communication, with implications for tumour survival and therapeutic development.
Venkatesh, H. S. et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549, 533–537 (2017).
Venkatesh, H. S. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539–545 (2019).
Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532–538 (2019).
Yu, K. et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature 578, 166–171 (2020).
Brooks, L. J. et al. The white matter is a pro-differentiative niche for glioblastoma. Nat. Commun. 12, 2184 (2021).
Wu, Y. et al. Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nat. Commun. 11, 6434 (2020).
Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108–119 (2018).
Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643–1660 e1617 (2020).
Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595–610 (2021).
De, I. et al. CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res. 76, 2552–2560 (2016).
Zhou, W. et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17, 170–182 (2015).
Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264–1272 (2013). This article describes the importance of tumour-associated macrophages in the brain tumour microenvironment and the utility of targeting a key macrophage dependency, CSF1R, for therapeutic benefit, setting the stage for later work addressing interactions between stem populations and tumour-associated macrophages.
Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).
Akkari, L. et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci. Transl. Med. 12 https://doi.org/10.1126/scitranslmed.aaw7843 (2020).
Chen, P. et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell 35, 868–884 e866 (2019).
Chen, P. et al. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 10, 371–381 (2020).
Takenaka, M. C. et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 22, 729–740 (2019).
Gangoso, E. et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell 184, 2454–2470 e2426 (2021).
Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192–1203 (2018).
Di Tomaso, T. et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16, 800–813 (2010).
Domenis, R. et al. Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLoS ONE 12, e0169932 (2017).
Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459–1468 (2018).
Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281–1298 e1226 (2021).
Friebel, E. et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell 181, 1626–1642 e1620 (2020).
Moore, G., Annett, S., McClements, L. & Robson, T. Top notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives. Cells 9 https://doi.org/10.3390/cells9061503 (2020).
Latour, M., Her, N. G., Kesari, S. & Nurmemmedov, E. WNT signaling as a therapeutic target for glioblastoma. Int. J. Mol. Sci. 22 https://doi.org/10.3390/ijms22168428 (2021).
Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761–765 (2006).
Lee, J. et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69–80 (2008).
Dong, Z. et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-0215 (2019).
Mancini, A. et al. Disruption of the beta1L Isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner. Cancer Cell 34, 513–528 e518 (2018).
Zhu, Z. et al. Zika virus has oncolytic activity against glioblastoma stem cells. J. Exp. Med. 214, 2843–2857 (2017).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016). This is the first article demonstrating efficacy of CAR T cell therapy in glioblastomas and shows that targeting IL-13Rα2 with this novel immunotherapeutic approach could safely induce regression in a phase I clinical trial, informing application of this technology to stem-specific targets.
O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9 https://doi.org/10.1126/scitranslmed.aaa0984 (2017).
Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101 (2017).
Weiss, T., Weller, M., Guckenberger, M., Sentman, C. L. & Roth, P. NKG2D-Based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 78, 1031–1043 (2018).
Cui, J. et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neuro Oncol. 21, 1436–1446 (2019).
Pellegatta, S. et al. Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci. Transl. Med. 10 https://doi.org/10.1126/scitranslmed.aao2731 (2018).
Chow, K. K. et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21, 629–637 (2013).
Vora, P. et al. The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell 26, 832–844 e836 (2020).
Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016).
Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13 https://doi.org/10.1126/scitranslmed.abe7378 (2021).
Wang, D. et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov. 11, 1192–1211 (2021).
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019). In this report of a phase I actively personalized vaccination trial, individualized vaccines developed from transcriptomic and immunopeptidomic analysis of patients displayed evidence of safety and activation of sustained immune responses against targeted antigens, including PTPRZ1, which enriches stem populations.
Frederico, S. C. et al. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front. Oncol. 11, 672508 (2021).
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994). This is the first article that provides evidence for and establishes our modern understanding of the classical CSC hypothesis, whereby stem populations are positioned at the apex of a developmental hierarchy essential for the initiation and maintenance of acute myeloid leukaemias.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003). Together with Singh et al. (2004), this is the first report of the identification of CSCs in glioblastomas and medulloblastomas, with prospective isolation of CD133+ cells that displayed stem cell properties, including capacity for self-renewal, tumour initiation and recapitulation of the original tumour on serial transplantation.
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).
O’Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).
Oskarsson, T., Batlle, E. & Massague, J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14, 306–321 (2014).
Ganesh, K. & Massague, J. Targeting metastatic cancer. Nat. Med. 27, 34–44 (2021).
Gonzalez, H. et al. Cellular architecture of human brain metastases. Cell https://doi.org/10.1016/j.cell.2021.12.043 (2022).
Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).
Steinbichler, T. B. et al. Cancer stem cells and their unique role in metastatic spread. Semin. Cancer Biol. 60, 148–156 (2020).
Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112 e114 (2019).
Lawson, D. A. et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131–135 (2015).
Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer. Nature 540, 552–558 (2016).
Berghoff, A. S. et al. Identification and characterization of cancer cells that initiate metastases to the brain and other organs. Mol. Cancer Res. 19, 688–701 (2021).
Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588–592 (2016).
Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).
Laughney, A. M. et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259–269 (2020).
Fumagalli, A. et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26, 569–578 e567 (2020).
Ganesh, K. et al. L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nat. Cancer 1, 28–45 (2020).
Er, E. E. et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat. Cell Biol. 20, 966–978 (2018).
Sirkisoon, S. R. et al. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene 39, 64–78 (2020).
Ren, D. et al. Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer. Cancer Res. 78, 2052–2064 (2018).
Chen, Q. et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533, 493–498 (2016).
Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002–1016 (2014).
Zeng, Q. et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature 573, 526–531 (2019).
Ferraro, G. B. et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat. Cancer 2, 414–428 (2021).
Jin, X. et al. A metastasis map of human cancer cell lines. Nature 588, 331–336 (2020).
Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017).
Tasdogan, A. et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature 577, 115–120 (2020).
Mashimo, T. et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603–1614 (2014).
Chen, J. et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015).
Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952–955 (2019).
Hubert, C. G. et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 76, 2465–2477 (2016). This is the first report of the use of three-dimensional brain tumour organoids for more physiologic and representative modelling of glioblastomas and metastatic tumours, enabling more precise investigation of tumour cellular architecture, cellular and phenotypic heterogeneity, microenvironmental gradients and cancer stem state biology.
Ogawa, J., Pao, G. M., Shokhirev, M. N. & Verma, I. M. Glioblastoma model using human cerebral organoids. Cell Rep. 23, 1220–1229 (2018).
Bian, S. et al. Genetically engineered cerebral organoids model brain tumor formation. Nat. Methods 15, 631–639 (2018).
Linkous, A. et al. Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 26, 3203–3211 e3205 (2019).
Pine, A. R. et al. Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. Cancer Discov. 10, 964–979 (2020).
Ballabio, C. et al. Modeling medulloblastoma in vivo and with human cerebellar organoids. Nat. Commun. 11, 583 (2020).
Jacob, F. et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180, 188–204 e122 (2020).
Jacob, F., Ming, G. L. & Song, H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat. Protoc. 15, 4000–4033 (2020). Together with Jacob et al. (2020)204, this report details the generation of a patient-derived glioblastoma organoid biobank with improved retention of features of the primary tumour, including histologic features, cellular composition and transcriptional profiles, and uses this approach to evaluate personalized targeted therapies and immunotherapies.
Heinrich, M. A. et al. 3D-bioprinted mini-brain: a glioblastoma model to study cellular interactions and therapeutics. Adv. Mater. 31, e1806590 (2019).
Tang, M. et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 30, 833–853 (2020).
Tang, M. et al. Rapid 3D bioprinting of glioblastoma model mimicking native biophysical heterogeneity. Small 17, e2006050 (2021).
Yi, H. G. et al. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat. Biomed. Eng. 3, 509–519 (2019).
Chadwick, M. et al. Rapid processing and drug evaluation in glioblastoma patient-derived organoid models with 4D bioprinted arrays. iScience 23, 101365 (2020).
Acknowledgements
The authors apologize to the authors of the many outstanding publications not referenced here owing to space restrictions. R.C.G is supported by US National Institutes of Health (NIH) grant F30CA217065. K.Y. is supported by the Computational Genomic Epidemiology of Cancer program at Case Comprehensive Cancer Center (T32CA094186), the Young Investigator Award in Glioblastoma from Conquer Cancer, the ASCO Foundation, and an RSNA research resident grant. M.E.H. is funded by the Joshua’s Wish Foundation. S.A. is funded by NIH grant R01NS115831, the Michael Mosier Defeat DIPG Foundation and the V Foundation (Connor’s Cure). J.N.R. is supported by NIH grants R35CA197718, R01CA238662 and R01NS103434.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests in relation to the work described.
Peer review
Peer review information
Nature Reviews Cancer thanks Maciej Lesniak and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Lineage infidelity
-
Process by which cells differentiated along a particular developmental lineage lose their original identity and assume a more primitive developmental state or display features of a distinct differentiated lineage.
- Single-cell sequencing
-
An array of methods to assess genomic, epigenomic or transcriptomic states of individual cells through next-generation sequencing approaches. These techniques allow resolution of distinct cellular populations, identification of new cell types or states, acquisition of information on expression dynamics and insights into cellular and tissue evolution, among other characteristics.
- DNA barcoding
-
Method of individually labelling single cells or a cellular population for tracking over time, with applications in cell tracing and reconstruction of evolutionary lineages. Cell labelling can be accomplished with lentiviral or CRISPR-based transduction approaches and interrogated with flow cytometry, sequencing or imaging, and analysis can be performed with single-cell resolution.
- Subventricular zone
-
Anatomic region in the brain situated along the lateral ventricles that contains populations of proliferative immature neural lineages. This region gives rise to more differentiated progeny through the process of neurogenesis, with possible links to gliomagenesis.
- Organoid
-
Three-dimensional, self-organizing heterogeneous cellular collections derived from stem-like populations and consisting of a variety of cell states used to model cellular interactions and higher-order functions of tissue systems, including tissue regeneration, maintenance and cellular connectivity in both neoplastic and non-neoplastic settings.
- Mitotic somal translocation
-
Characteristic migratory behaviour of outer radial glial cells in which the cell body rapidly moves from the outer subventricular zone towards the cortical plate immediately before cell division during neurogenesis.
- Oncohistone mutations
-
Mutations in a variety of histone proteins that promote cancer growth primarily through disruptions in the global histone post-translational modification landscape and disrupted epigenetic regulation. In brain tumours, common mutations include K27M (histone H3) in diffuse intrinsic pontine gliomas and G34V/R (histone H3) in paediatric glioblastomas, among others.
- RNA velocity analysis
-
Method to estimate the rate of change of transcriptional states of cells in single-cell sequencing studies through comparison of the ratio of newly transcribed (unspliced) transcripts to mature transcripts (spliced) and to infer expression dynamics and future cellular states.
- Temozolomide
-
Alkylating chemotherapy agent with blood–brain barrier penetrance that serves as standard-of-care treatment for patients with glioblastoma alongside surgical resection and radiotherapy.
- Branched and neutral evolution
-
Different models to describe the emergence of intratumoural genetic heterogeneity and development of lineage trajectories in cancers. Branched evolution models suggest that heterogeneous clones emerge on the basis of a selective advantage and evolve in parallel, while neutral evolution models posit that intratumoural heterogeneity is driven primarily by random mutations and genetic drift without strong selective forces. Branched and neutral evolution models describe relatively high intratumoural heterogeneity, while linear or punctuated evolution models consist of lower heterogeneity at a given time point driven by single clones with increased fitness.
- Extrachromosomal circular DNA
-
Collections of circular DNA sequences lacking centromeres that exist outside chromosomes and which can be replicated and differentially segregated to daughter cells during cell division, with important implications for intratumoural heterogeneity and cancer evolution. Extrachromosomal circular DNA can lead to massive amplification of oncogenes and products facilitating therapy resistance, can consist of highly rearranged genomic sequences and is thought to arise through the process of genomic shattering (chromothripsis) with disrupted DNA damage repair pathways, although competing models exist.
- Microvascular proliferation
-
Characteristic histologic hallmark of glioblastomas referring to pathogenic glomeruloid proliferation of mitotically active and multilayered hyperplastic endothelial cells secondary to high angiogenic activity of VEGF that may be associated with areas of hypoxia and necrosis.
- Circadian rhythm
-
Cell-intrinsic or multisystem process that occurs on a 24-h cycle and is maintained through cyclical production and degradation of circadian protein complexes or entrained through endocrine signalling mechanisms. While circadian rhythms on the whole-organism level can be controlled through exposure to light cycles, independent molecular clocks exist within many individual single cell types driven by peripheral oscillator transcriptional networks, including CLOCK, BMAL1, PER and CRY.
- Chimeric antigen receptor (CAR) T cells
-
Synthetic T lymphocytes containing an engineered T cell receptor targeted against a specific antigen with optimized intracellular signalling components to coordinate antitumour immune responses and facilitate cancer cell killing in experimental and clinically validated immunotherapies. CAR T cells can be expanded in vitro and then infused into patients, serving as a ‘living drug’ with capacity to expand in vivo and generate memory responses.
- Synthetic Notch receptor
-
Customized receptor generated through cellular engineering approaches to sense particular extracellular signals and coordinate a specific programmable intracellular response via a regulatory transmembrane domain and an effector intracellular domain such as a transcription factor. This highly tuneable tool enables sensing of specific signals to be coupled with a downstream effector response via a synthetic biology approach, with applications in cancer immunotherapy and beyond.
Rights and permissions
About this article
Cite this article
Gimple, R.C., Yang, K., Halbert, M.E. et al. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer 22, 497–514 (2022). https://doi.org/10.1038/s41568-022-00486-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-022-00486-x
This article is cited by
-
CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD+/NADH ratio
Journal of Experimental & Clinical Cancer Research (2025)
-
Nuclear receptor E75/NR1D2 promotes tumor malignant transformation by integrating Hippo and Notch pathways
The EMBO Journal (2024)
-
Microenvironmental reorganization in brain tumors following radiotherapy and recurrence revealed by hyperplexed immunofluorescence imaging
Nature Communications (2024)
-
Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression
The EMBO Journal (2024)
-
SOX10 mediates glioblastoma cell-state plasticity
EMBO Reports (2024)